Pharma News

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

Hong Kong - A multinational study led by the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) has found promising results for D3S-001, a next-generation KRAS-G12C inhibitor de...

RADNOR, Pa. – Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company valued at approximately $1 billion and showing strong momentum with a 24% gain year-to-date, announced toda...

Philippine pharmaceutical company MedEthix Inc. received international recognition for its pioneering women's health initiative, the MedEthix Endometriosis Masterclass (MEM), at this year&...

The sale brings attention back to privacy concerns as Regeneron now controls genetic data from millions of 23andMe customers.

Drug manufacturers will now have to commit to the new pricing model to avoid regulatory action in the US.

2024 saw the highest number of biosimilars approved by the US Food and Drug Administration (FDA) in a calendar year, with this year set to break this record again, analysis suggests.

Incyte INCY announced that the FDA has approved its new drug, Zynyz (retifanlimab-dlwr), a PD-1 inhibitor, for treating a new cancer indication.

Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics.

Riding its Peloton buyout, Merck rolls to third FDA nod for potential blockbuster Welireg

Roger Hajjar, MD, on Helping to Bring Preclinical Gene Therapy Research to First-In-Human Trials

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals’ efimosfermin, a drug ready to hit Phase III trials for the treatment of...